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ABSTRACT
Aim and Objective: Most conventional oral drug products, such as tablets and capsules, are formulated to release the active drug immediately after 
oral administration, to obtain rapid and complete systemic drug absorption and onset of accompanying pharmacodynamic effects. The term modified 
release drug product is used to describe that alter the timing and or the rate of release of the drug substances. The objective of the present study was 
to formulate and evaluate the sustained release matrix tablet of venlafaxine hydrochloride. 
Methods: Venlafaxine hydrochloride is a structurally novel antidepressant for oral administration. It is widely prescribed for the treatment of 
depression, generalized anxiety disorder, and social anxiety disorder. Venlafaxine hydrochloride is currently available as immediate release tablet 
and as an extended release capsules under the brand names of Effexor (WYETH AYERST) and Effexor XR (WYETH AYERST). The biological half-life of 
venlafaxine very short (5 h) and the dose is to be taken 2–3 times a day and the recommended maximum daily dose is 75–450 mg/day.
Results: Venlafaxine hydrochloride is an antidepressant and so it is to be taken for quite a long period. Hence, to reduce the dosing frequency, simple, 
lower cost sustained release tablets of venlafaxine were preferred for the development 
Keywords: Venlafaxine hydrochloride, Hydroxypropyl methylcellulose, Matrix tablets.
INTRODUCTION
A modified-release dosage form is defined as one for which the drug-
release characteristics of time course [1].
EXPERIMENTAL WORK
Preformulation studies
Preformulation testing is the first step in the rational development of 
dosage form of drugs. It involves the application of biopharmaceutical 
principles to the physiochemical [2] parameters of a drug with the 
goal of designing an optimum drug delivery system that is stable, 
bioavailable and can be mass produced [3].
Analytical evaluation
1. Ultraviolet (UV) spectroscopic analysis.
2. Infrared (IR) spectroscopic analysis.
PREPARATION OF CALIBRATION CURVE OF VENLAFAXINE 
HYDROCHLORIDE
Procedure
Preparation of primary stock solution
A primary stock solution of venlafaxine hydrochloride was prepared by 
dissolving 100 mg of pure drug in purified water in 100 ml of volumetric 
flask and volume made up to 100 ml of with purified water.
Preparation of sample solution
From the primary stock solution, aliquots ranging from 0.05 ml to 
0.5 ml were pipetted out and diluted to 10 ml with purified water to get 
the concentration of 5 µg/ml–30 µg/ml. The absorbance was measured 
at 274 nm using UV-visible spectrophotometer.
IR spectroscopic analysis
The identification of pure drug and excipients was performed using 
Fourier-transform (FT-IR) spectroscopy. IR absorption spectra of the 
pure drug and with different excipients were [4] taken using KBr pressed 
pellet method [5]. The pellets were prepared by triturating sample and 
obtained spectra were compared with the reference UV spectroscopic 
analysis [4]. [6] Pharmaceutical products designed for oral drug delivery 
are mainly conventional drug delivery systems [7] Sustained drug action 
pre determined rate by maintaining a relatively constant [8] The effective 
drug level in the body with concomitant minimization of undesirable 
side effects [9] The targetted drug action by busing carriers or chemical 
derivatives to deliver drug to a particular target cell type [10] Targetted 
release dosage forms may have either immediate or extended release 
characteristics [11].
FORMULATION DEVELOPMENT
The study involves the formulation of venlafaxine sustained release 
matrix tablet.
Procedure
1. Weigh and dissolve ethyl cellulose 95% in ethanol to prepare 2%w/w 
solution.
2. Weigh venlafaxine hydrochloride, hydroxypropyl methylcellulose 
(HPMC), tale, and magnesium stearate and shift through ASTM#40.
3. Mix the sifted materials for 5 min in a poly bag.
4. Add ethyl cellulose solution to dry mix until getting coherent mass: 
If required add sufficient ethanol 95%.
5. Air dries the granules and keeps the granules in vacuum oven for 
overnight.
6. Sift the dried granules through ASTM#20.
7. Weigh talc and sift through ASTM#60.
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8. Blend the sifted granules and in a poly bag for 30 min.
9. Weigh and sift magnesium stearate through ASTM#40.
10. Lubricate the blend with sifted magnesium stearate for 2 min.
11. Compress the tablets using 12 mm flat punches with break line on 
upper punch.
EVALUATION OF TABLET
The tablets were evaluated for the following characteristics.
Weight variation
Weigh and dissolve ethyl cellulose 95% in ethanol to prepare 2% W/W 
solution,Mix the sifted materials for 5mts in a poly bag  and the each 
Venlafaxine hydrochloride weight 84.86mg equal to venlafaine 75mg 
are shown Table 1.
The test ensures that all the tablets in each batch are of same potency, 
within reasonable limits. According to the USP weight variation test. 
The specification of the weight variation limits as per USP is given in 
the following Table 2.
According to the USP Weight variation test,20 tablets were weighed 
individually and collectively. Average weight per tablet was calculated 
from the collective weight. Then the weights of the individual tablets 
were compared with the average weight to determine the weight 
variation.
Drug content
A total of l0 tablets are triturated using mortar and pestle. A quantity of 
powder weighed equivalent to 84.86 mg of drug was transferred to 100 ml 
of standard flask and volume made up to 100 ml with purified water.
Hardness test
A total of 10 tablets from each batch were used and the hardness was 
expressed in kg/mm2.
Friability
Friability test was performed to assess the effect of friction and shock 




Standard calibration curve of venlafaxine hydrochloride
The absorbance was measured at 274 mn against purified water as 
blank. The values are given in Table 3.
IR spectroscopy study
FT-IR technique was used for the identification of venlafaxine 
hydrochloride and the blend of finalized formula (F6). The obtained 
results are given in Table 4.
The IR Spectral studies of  blend were carried out to study the interaction 
between the drug and super disintegrants used. It showed that IR 
spectrum of pure drug venlafaixne hydrochloride final lubricated blend 
of table 5 shown some additional peak due to the presents of excipients. 
Thus on the basis of FT-IR studies, we can conclude that, the drug is 
compatible with ecipients.  The results are shown in Table 5.
Flow properties of blend
Six formulations are prepared and the lubricated blend was evaluated 
for various parameters as follows.
Table 1: Composition of venlafaxine hydrochloride sustained release matrix tablet
S. No. Ingredients F1 F2 F3 F4 F5 F6
mg/tablets
1 Venlafaxine hydrochloride 84.86 84.86 84.86 84.86 84.86 84.86
2 Lactose monohydrate 55 55 55 - - -
3 Hypromellose (HPMC K15M) 300 - 200 200 150 150
4 Hypromellose (HPMC K100M) - 300 100 100 100 150
5 Ethyl cellulose 2%w/w - - - 16.66 16.66 16.66
6 Ethanol (95%) - - - qs qs qs
7 Talc 5 5 5 27.62 26.67 27.99
8 Magnesium stearate 450 450 450
84.86 mg of venlafaxine hydrochloride equivalent to venlafaxine 75 mg, HPMC: Hydroxypropyl methylcellulose
Table 2: Specification for weight variation of tablets as per USP
Average weight of tablet % deviation
130 mg or less ±110
>130 mg but <324 mg ±7.5
324 mg or more ±5
Table 3: Standard curve for venlafaxine hydrochloride







Table 4: IR spectra data for venlafaxine hydrochloride
Frequency Hz Group assigned
3325 0-H stretching vibration
2929.13 C-H stretching
3001.96 C-H aromatic stretching
1273.6 C-N stretching vibration
1366 C-N stretching vibration
1582.77 C=C stretching vibration (aromatic)
1612.11 C=C stretching vibration (aromatic)
1512.64 C=C stretching vibration (aromatic)
1079.79 O-H stretching vibration
830.55 C-H deformation vibration
IR: Infrared
Table 5: IR spectra data for blend
Frequency Hz Group assigned
2920.18 C-H stretching
1020.18 C-O-C stretching vibration
1250.79 O-H stretching (secondary alcohol)
838.26 C-H deformation
1600 C=C stretching vibration
1500 C=C stretching vibration
IR: Infrared
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Angle of repose
The present study was undertaken to formulate Venlafaxine 
hydrochloride matrix  tablet  with three polymers namely Lactose 
mono hydrorate , hypromellose , ethyl cellulose and in combination 
of three super disintegrants and by dry granulation technique. Before 
compression of the granules physical characters such as bulk density, 
tapped density, angle of repose, compressibility index and hausner ratio 
was determined and tabulated in Table 6.
Bulk density
The bulk density of various granules is measured using graduated 
cylinder. The bulk density was found in the range of 0.52–0.60 g/cm. 
The results are given in Table 6.
Tapped density
The tapped density of lubricated blends was determined using 
measuring cylinder. The tapped density was found in the range of 0.65–
0.72 g/cm. The results are given in Table 6.
Compressibility index and Hausner ratio
The compressibility index and Hausner ratio of various lubricated 
blends were calculated using bulk density and tapped density data.
• The compressibility index was found in the ratio of 16.66–21.21%.
• The present study was undertaken to formulate Venlafaine 
hydrochloride matrix tablet dispersible tablet with three polymers 
namely sodium starch glycolate, cros carmellose sodium and in 
combination of three super disintegrants and by dry granulation 
technique. Before compression of the granules physical characters 
such as bulk density, tapped density, angle of repose, compressibility 
index and hausner ratio was determined and tabulated in Table 6.
The angle of repose of all batches was found between 20° and 30° 
Wh1C1’l indicates that the blends are having good flow property. The 
results of compressibility index (l6.66–21.21%) and Hausner ratio 
(1.2–1.25) indicate that the blends are having fair to good flow property.
EVALUATION OF VENLAFAXINE HYDROCHLORIDE SUSTAINED 
RELEASE MATRIX TABLETS
Weight variation
The compressed tablets were evaluated for physical properties and the 
results are tabulated for Hardness test, Thickness test, Friability test, % 
of weight variation test and Estimation of drug content values showed 
in Table 7.
The prepared tablets were evaluated for weight variation. All the tablets 
are the acceptable range of weight variation as per USP specification, 
i.e., less than 15%. The results are given in Table 7.
Thickness
The thickness of the tablets was determined by Vernier caliper and 
found in the range of 5.40–5.44 mm. The results are given in Table 7.
Hardness
Hardness of tablets was calculated by Monsanto Hardness tester and 
found in the range of 2.5–2.7 kg/cm2. The results are given in Table 7.
Friability
Tablets were evaluated using Roche friabilator and friability of tablets 
was observed in acceptable range of 0.28–0.52% (<1%), which shows 
that the tablets are mechanical stable and could handle the rigors of 
transportation and handling. The results are given in Table 7.
Estimation of drug content
The tablets were evaluated for drug content by assay method. The drug 
content was found in the range of 99.8–l00.4%. The results are given 
 Table 6: Precompression studies of powder blend
Batch code Angle of repose Bulk density (g/cm3) Tapped density (g/cm3) Compressibility index (%) Hausner ratio
F1 28°81 0.52 0.66 21.21 1.25
F2 29°68 0.56 0.68 17.64 1.21
F3 27°92 0.52 0.65 20 1.25
F4 26°56 0.58 0.72 19.44 1.24
F5 25°74 0.59 0.72 18.05 1.22
F6 26°10 0.60 0.72 16.66 1.2
Table 7: Post compression studies of Venlafaxine hydrochloride matrix tablet
Batch code Thickness (mm) Hardness (kg/cm2) Friability (%) Drug content (%) Weight variation (mg)
F1 5.41±0.01 2.83±0.41 0.52 100.2 450±1.08
F2 5.41±0.02 3.00±0.45 0.50 101.3 450±1.03
F3 5.40±0.02 3.17±0.26 0.45 99.87 450±1.29
F4 5.20±0.02 3.33±0.26 0.32 100.3 411±1.03
F5 5.10±0.04 3.25±0.27 0.34 99.8 361±084
F6 5.21±0.02 3.42±0.20 0.28 100.4 411±0.78
Table 8: In vitro drug release profile for batch F1 to F6
Time (h) Cumulative % drug release
F1 F2 F3 F4 F5 F6
77.84 86.1 79.4 49.44 60.72 13.62
79.4 92.2 82.3 50.26 66.36 26.28
83.2 94.8 90.8 51.0 69.36 38.16
87.6 95.3 96.9 53.16 70.44 49.72
89.8 96.8 102.2 55.96 72.0 55.8
92.16 97.8 61.08 74.52 60.05
94.82 98.2 63.72 77.16 62.52
97.6 99.82 64.8 79.44 65.16
98.8 101.6 67.44 82.08 68.16
100.9 69.72 84.36 71.52
74.16 87.0 75.72
78.36 89.52 79.08
Table 9: Release profile of innovator product (EffexorTm‑XR)
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in Table 7.
IN VITRO DISSOLUTION STUDY
In vitro drug release study of venlafaxine hydrochloride sustained 
matrix tablet was carried out in purified water at temperature 37±0.5’c 
with basket rotation at 100rpm for 12hrs.
In order to find out the order of release and mechanisms, which was 
predominantly influence the drug release from the tablets, the in vitro 
dissolution data was subjected to graphical treatment is percentage 
cumulative drug release VS time.
In vitro dissolution profile of first three batches (F1, F2, F3) shown 
burst release. Among the net three batches (F4, F5, F6) F6 shown good 
control in initial time  points( upto 4th hr) and matching with release 
profile of EFFEOR XR are shown in Table 8.
Release profile of innovator product was mentioned in Time in the 
ranges of 2,4,8,12,24 vs average of venlafaxine hydrochloride are 
shown in Table 9. 
Here the data was plotted as a graph according to Zero order plot, 
Higuchi plot, korsmeyer & peppas plot , cumulative percentage of drug 
release along Y-axis and square root of time (hrs) along-axis are shown 
Table 10. 
STUDY OF DRUG RELEASE KINETICS
The data were plotted as graph according to zero-order kinetics, cumulative 
percentage of drug release along Y-axis and time (h) along X-axis.
The data were plotted as a graph according to Higuchi’s plot, cumulative 
percentage of drug release along Y-axis and square root of time (h) 
along X-axis. The plot was found to be linear and the linear regression 
coefficient value is R2=0.963l so it is obvious that the drug release 
obeys gel diffusion mechanism.
The data were plotted as a graph according to Peppers plot log 
cumulative percentage of drug release along Y-axis and log time (hrs) 
along X-axis.
DISCUSSION
The main goal of this work to develop sustained release matrix 
tablets of venlafaxine hydrochloride and to find out the effect of 
polymers on the various parameters of tablets such as dissolution 
and drug release.
Venlafaxine hydrochloride is an antidepressant having short biological 
half-life (5 h). Hence, to reduce the dosing frequency and the side 
effects, sustained release matrix tablet was formulated.
Three formulations were prepared by direct compression using 
different grades of hydroxypropyl methylcellulose polymers such as 
Kl5M and KIOOM. Further, three formulations were taken with ethyl 
cellulose (2 %w/W) dispersion in ethanol (95%) by wet granulation 
process.
SUMMARY
Venlafaxine hydrochloride is a structurally novel antidepressant for 
oral administration. The drawback of venlafaxine hydrochloride is 
short half-life. To give dose for long-term therapy with multidose 
regimen, patient compliance is the difficult to achieve. Hence, 
to reduce the dosing frequency, simple, lower cost sustained 
release tablets of venlafaxine hydrochloride were preferred for the 
development.
Analytical method was developed for venlafaxine hydrochloride using 
UV spectrometer at Kmax of 274 mn. It obeys the Lambert’s law between 
5 and 30 µg/ml. FT-IR study of pure drug, excipients, and blend of final 
formula was studied and the result confirms that the drug is compatible 
with other excipients. Three formulations of venlafaxine hydrochloride 
tablet were prepared by direct compression process, with different 
ratio of HPMC Kl5M and KIOOM. The dissolution of compressed tablets 
showed initial burst release.
Hence, three batches were formulated using ethyl cellulose (2%w/w) 
dispersions in ethanol (95%) and using HPMC KISM and KIOOM by 
wet granulation process. The formulated tablets are shown good 
control initial time points. Among the batches taken, batch F6 shown a 
controlled release characteristics. All the formulations were evaluated 
for physical parameters such as weight variation, thickness, hardness, 
and friability.
The results indicate that all the formulations were within the acceptable 
limit.
CONCLUSION
The venlafaxine hydrochloride sustained release matrix tablets shown 
controlled release profile as per the release profile of the innovator is 
EffexorTm_XR. The sustained release of this matrix tablet reduces the 
dosing frequency and reduces the side effects, by which in a long-term 
therapy, it may be useful as a product with patient compliance for the 
treatment of major depression disorder.
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